On February 2, 2026, MIRA Pharmaceuticals, Inc. announced the start of dosing in the final phase of its clinical trial for Ketamir-2, with 50 healthy volunteers dosed so far and plans for further studies in 2026. The company aims for FDA Fast Track designation for Ketamir-2 due to its focus on treating chemotherapy-induced peripheral neuropathy.